Overview of Nystaderm-S

Property	Description
Active ingredient	Nystatin
Form	Oral Suspension (Pumplösung)
Pharmacological class	Antifungal (Polyene Macrolide)
Common use	Management of Candida overgrowth
Origin	Natural compound (Streptomyces noursei)

What Type of Medicine is Nystaderm-S?

Nystaderm-S is a medicinal monopreparation classified as an antifungal agent, specifically targeting infections caused by yeast and fungi. Its sole therapeutic component is the active ingredient Nystatin, which places it within the distinct pharmacological group of polyene macrolides. This structural category validates the medicine's specific targeting capabilities against yeast infections.

This medicine, often associated with the manufacturer DERMAPHARM AG, is uniquely characterized as a locally acting antifungal agent. It is formulated to exert its effects directly at the site of application within the digestive tract, without being substantially absorbed into the general circulation. Nystatin-containing products are primarily used for intestinal candidiasis, reinforcing its application as a non-systemic agent.

Composition, Form, and Natural Origin

The core component, Nystatin, is a natural compound derived from the soil bacterium Streptomyces noursei, a characteristic distinguishing it from purely synthetic antifungals. Nystaderm-S is supplied as an oral suspension (often referred to as a Pumplösung), which is a liquid preparation of the active substance finely dispersed in an aqueous base.

This specific dosage form is essential for oral and oropharyngeal administration, allowing the Nystatin to be distributed uniformly across the mucosal surfaces. The composition ensures the medication maintains direct, prolonged contact with the target site throughout the alimentary canal.

General Purpose of Nystatin Therapy

The general purpose of Nystaderm-S is to reduce or eliminate the proliferation of yeast and fungal organisms, most notably those from the Candida genus. The medication achieves this by deploying a direct mechanism that disrupts the structural integrity of the fungal cell membrane, primarily through binding to ergosterol. This targeted action is essential for the effective control of fungal overgrowth, ensuring that the population of pathogenic fungi is substantially inhibited or destroyed at the site of infection.

Regulatory References

What side effects are possible with Nystaderm-S?

Possible Side Effects and Safety Information

The safety profile for Nystaderm-S, an antifungal oral suspension, is characterized by adverse reactions that are primarily localized to the gastrointestinal tract, consistent with its limited systemic absorption. Officially documented effects on the Gastrointestinal System include nausea, vomiting, and diarrhea, sometimes reported occasionally following large oral doses, as noted in certain regulatory documents.

Hypersensitivity and Serious Reactions

Reactions affecting the skin and immune system are documented, though generally classified as rare. Rash and urticaria have been reported rarely. More serious adverse reactions, while very rarely reported, include severe conditions such as Stevens-Johnson syndrome and systemic manifestations of hypersensitivity like anaphylactoid reaction, bronchospasm, and facial swelling, as listed in regulatory labeling.

Population and Use Restrictions

The official labeling includes specific safety considerations for certain populations. For pregnant individuals, the preparation is classified as Pregnancy Category C; its use should be determined only if clearly needed, as potential for fetal harm is not known. Caution is also advised for nursing mothers since it is not known if the medication is excreted in human milk. The preparation is formally contraindicated in patients with a history of hypersensitivity to Nystatin. It is important to note the restriction that this oral suspension should not be used for the treatment of systemic mycoses due to its local mechanism of action.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Nystaderm-S (Nystatin oral suspension) defines the overdose profile primarily by its negligible systemic absorption.

Documented Overdose Manifestations

Classification	Official Regulatory Statement
Toxicity Profile	Overdosage causes no systemic toxicity and no reports of serious toxic effects due to insignificant absorption from the gastrointestinal tract.
Clinical Signs	Manifestations are strictly confined to the digestive system, including gastrointestinal upset, nausea, vomiting, and diarrhea.
Management	No specific antidote is known. Management is symptomatic and supportive, addressing the manifested GI effects.

Regulator-Mandated Emergency Actions

Official guidance requires specific actions to be taken in the event of suspected overdosage:

Contact a Poison Control Centre or a healthcare professional for immediate advice and assessment.
Seek immediate medical attention or call emergency services if the individual shows signs of a general medical emergency, such as collapse, difficulty breathing, or loss of consciousness.

This structure reflects the regulatory finding that overdose effects are local and transient, reserving emergency services for general life-threatening symptoms, not a specific drug-induced systemic toxicity.

Therapeutic Uses of Nystaderm-S

What Nystaderm-S Treats: Main Uses and Benefits

Easing Pronounced Symptoms of Acute Manifestations

Nystaderm-S is primarily applied across domains where additional symptomatic support is needed to address related physical discomfort. The medication is commonly used across conditions presenting with acute episodes characterized by specific symptoms. For example, it is relevant for easing symptoms associated with conditions involving inflammatory or irritative processes. It may assist with managing symptoms that interfere with daily comfort.

Providing Supportive Relief During Symptom Escalation

This medication is commonly used across conditions presenting with acute episodes characterized by periods of heightened symptoms. It is applied during phases of increased distress or discomfort, where symptoms become more noticeable. Nystaderm-S contributes to easing the overall symptom load and supports patients during difficult episodes by easing distress, providing supportive relief when symptoms interfere with routine activities. The treatment is relevant in contexts involving heightened systemic burden. It is commonly used to help with symptoms that may become intense or disruptive.

Quick Fact: Supportive management for acute symptoms

Managing Conditions with Disruptive Symptom Patterns

The treatment is relevant in clinical settings that involve acute or unstable symptom patterns, generally used when symptoms become more noticeable. It assists with maintaining functional stability and is considered relevant for easing the impact of symptoms that may temporarily affect daily comfort.

Regulatory References

U.S. Food and Drug Administration

Eligibility and Restrictions for Use

Who Can and Cannot Use Nystaderm-S?

The eligibility for Nystaderm-S (Nystatin Oral Suspension) is strictly defined by government regulatory documents, focusing on patient history, age, and the scope of the infection being treated.

Contraindications and Restrictions

Nystaderm-S is absolutely contraindicated for patients who have a known history of hypersensitivity (allergy) to nystatin or to any of the other components in the suspension. This is the primary rule for non-eligibility.

Systemic Use is Prohibited: The medication must not be used for the treatment of systemic mycoses (widespread internal fungal infections), as it is intended only for localized treatment within the digestive tract.

Age and Physiological Eligibility

Use of Nystaderm-S is established across a wide range of ages.

Population Group	Official Eligibility Status
Adults and Children	Use is established and permitted.
Infants and Neonates	Use is established (including premature and low-birth-weight infants).
Pregnant Women	Use is restricted; should be given only if clearly needed (Pregnancy Category C).
Nursing Mothers	Use requires caution because it is unknown whether the drug is excreted in human milk.

No specific restrictions regarding the elderly or patients with kidney or liver impairment are formally listed as contraindications in standard labeling, although some documents note the potential for trace systemic absorption in patients with renal impairment.

What should I know about interactions with other medicines?

The official regulatory profile for Nystaderm-S (Nystatin Oral Suspension) is fundamentally defined by its pharmacokinetic characteristics. Governmental prescribing information confirms that Nystatin is negligibly absorbed into the bloodstream from the gastrointestinal tract. This profile means the medicine generally does not engage in systemic metabolic or transporter pathways, such as those involving CYP enzymes or P-glycoprotein. Consequently, the typical pharmacokinetic interactions that alter the systemic exposure of co-administered medicines are not officially documented.

Interaction constraints are primarily focused on the local site of administration.

Documented Local Interactions and Restrictions

Contraindicated Combinations: Co-administration with certain biological products, such as allogeneic cultured keratinocytes/fibroblasts, is formally prohibited by regulatory bodies. This restriction results from the antifungal activity of Nystatin, which may cause degradation and compromise the efficacy of these specific cell-based products.
Pharmacodynamic Conflict: The local antifungal function of Nystatin can counteract the intended effect of other oral agents. Regulatory documents classify the concurrent use with probiotic yeasts, such as Saccharomyces boulardii, as a potential conflict, requiring avoidance or use of an alternative agent.
Food and Herbal Products: No specific interactions with food, alcohol, or common herbal products are explicitly listed in the official prescribing information.

Population-Specific Caution

Official labeling notes that in patients with renal insufficiency, significant plasma concentrations of Nystatin may occasionally occur during oral therapy. This population-specific consideration represents an exception to the general non-systemic absorption profile.

Mechanism of Action

Selective Targeting and Cellular Lysis

Nystaderm-S initiates a physical disruption cascade focused on the fungal cell membrane. The active ingredient, Nystatin, directly binds to ergosterol, which is the principal sterol in fungal cell membranes, thereby forming transmembrane pores. This binding demonstrates high selectivity for the ergosterol molecule over cholesterol, which is the primary sterol in mammalian cell membranes.

The formation of these pores turns Nystatin into an ionophore, which compromises the cell's selective permeability. This mechanical defect causes an uncontrolled, rapid efflux of essential internal components, most notably potassium ions ( K^+). The loss of the cell's electrochemical gradient and osmotic balance results in the cessation of fungal cell viability, producing a fungicidal effect which involves the physical destruction of the cell.

Dosage and Administration Information

How to Use Nystaderm-S: Administration Guidelines

Nystaderm-S, an oral suspension containing Nystatin (100,000 units/mL), is used exclusively via the oral administration route for local action within the alimentary canal. This medication is not intended for the treatment of systemic mycoses (infections throughout the body).

Administration Technique and Frequency

Prior to measuring the dose, the oral suspension must be shaken well. A fundamental principle of its administration is that the dose must be retained in the mouth for as long as possible before being swallowed. This technique ensures that the active ingredient maintains prolonged contact with the affected oral tissues. The standard schedule requires administration multiple times daily, typically three or four times, and some labels recommend taking the dose after meals.

Labeled Dosing and Course Duration

Standard dosing regimens vary slightly by region and indication. For adult oral candidiasis, the regimen is commonly 400,000 to 600,000 units per dose. For infants and young children, a lower dose is specified, often 200,000 units four times daily, with specialized administration instructions to place the dose into each side of the mouth.

Treatment duration is not flexible. For oral candidiasis, use must continue for at least 48 hours after symptoms have cleared, while intestinal use often requires continuation for two to three days after symptom resolution to prevent relapse. This fixed minimum course duration is a key procedural requirement.

Recent Clinical Evidence

Nystaderm-S: Recent Clinical Evidence

Overview of Nystatin and Triamcinolone Acetonide Research

Nystaderm-S combines the antifungal agent nystatin with the corticosteroid triamcinolone acetonide. Research on this fixed-dose combination (FDC) formulation has primarily focused on its use in treating cutaneous candidiasis complicated by inflammation. Studies have investigated whether the combination offers different clinical results compared to either agent used alone.

Key Research Findings

Clinical trials have generally centered on evaluating therapeutic response, which often includes the time to achieve clearance of the fungal infection and reduction in inflammatory symptoms such as redness and itching.

Research has explored the tolerability of Nystaderm-S, with common adverse events typically reported as mild, localized reactions at the application site. These reactions may include temporary stinging, burning, or irritation, which are frequently associated with the use of topical corticosteroids.

Summary of Study Outcomes

Area of Evaluation	Research Focus
Antifungal Activity	Studies evaluate Nystatin's capacity to inhibit the growth of Candida albicans on the skin.
Anti-Inflammatory Response	Trials assess the contribution of Triamcinolone Acetonide in managing localized swelling and erythema.
Safety and Tolerability	Investigators monitor for systemic absorption and local skin reactions, particularly with extended use.

It is important to note that the clinical data supporting Nystaderm-S evaluates its use strictly for its approved indication—fungal skin infections where inflammatory symptoms are prominent.

Key Studies & References Clinical Guideline: Management of Superficial Fungal Infections (relevant national society guideline)

Frequently Asked Questions (FAQ)

Common questions about Nystaderm-S (FAQ)

Q: Is Nystaderm-S a corticosteroid or does it have a steroid in it?

A: According to the official product information, Nystaderm-S oral suspension is a monopreparation, meaning it contains only one active ingredient. That ingredient is the antifungal agent, nystatin. Regulatory documents do not describe this oral suspension as containing a corticosteroid or any other type of steroid.

Q: How long is Nystaderm-S typically prescribed for?

A: Official guidelines indicate that the medicine should be continued for a minimum of at least 48 hours after symptoms have visibly cleared. This approach is intended to help prevent the infection from returning. The full treatment duration is determined by the healthcare provider.

Q: Is there a maximum amount of time Nystaderm-S can be used safely according to regulators?

A: Official documents define the length of treatment by instructing the user to continue use for a minimum period after symptoms have cleared. However, a specific maximum limit or cap on the total duration of treatment is not typically specified in the prescribing information.

Q: What happens if I forget to apply a dose of Nystaderm-S?

A: Patient information commonly advises that if you miss a dose, you may apply the forgotten dose as soon as you remember. Information commonly suggests that if it is almost time for the next scheduled dose, the missed dose is skipped. It is generally advised to follow the prescribed frequency.

Q: Is it possible to be allergic to Nystaderm-S?

A: Yes, it is possible to be allergic to the ingredients in Nystaderm-S. Official documents state that the medicine is formally contraindicated (must not be used) in people with a known history of hypersensitivity or allergy to nystatin or any other components in the suspension.

Q: What should I do if the treated area gets worse after starting Nystaderm-S?

A: Regulatory documents advise that if irritation or sensitization occurs—such as a persistent rash or severe reaction—while using the medicine, then its use should generally be discontinued. Regulatory documents advise that worsening may be associated with the need to review the treatment plan with a healthcare provider.

Q: What happens if Nystaderm-S accidentally gets into my eyes or mouth?

A: Nystaderm-S is formulated and intended only for oral use (inside the mouth). While official guidance for oral suspensions does not always detail eye exposure, general product safety advice for eye exposure suggests reviewing the situation with a healthcare provider or poison control centre.

Q: What do patient information leaflets typically say about stopping Nystaderm-S use?

A: Official instructions emphasize the importance of completing the full course of treatment, which means continuing for at least 48 hours after symptoms have cleared. Continuing use for this duration is intended to prevent relapse.

Q: Does Nystaderm-S treat the cause of the condition or just the symptoms?

A: Official information describes the action of the medicine as having a fungicidal effect. This means its mechanism of action is focused on the cause—it works to physically destroy the fungal cells themselves—rather than just masking the symptoms of the infection.

Q: Is Nystaderm-S available over the counter or do I need a prescription?

A: The medicine Nystatin oral suspension, which is the preparation described as Nystaderm-S, is generally classified as a prescription-only medicine in many major countries. It requires a prescription from a licensed healthcare provider to be dispensed.

Q: Can Nystaderm-S be used on different parts of the body, like the face or groin area?

A: The official labeling for Nystaderm-S oral suspension states it is intended exclusively for local action within the alimentary canal (mouth and digestive tract). The labeling confirms the authorized route is oral and for localized action within the alimentary canal.

Q: Is it normal for the cream to sting or feel itchy when I first start using Nystaderm-S?

A: The most common officially documented side effects for this specific oral suspension formulation are related to the gastrointestinal system, such as nausea, vomiting, or diarrhea. Skin reactions like rash or hives have been reported rarely. Any sensation of stinging or itching is a factor to consider for review with a healthcare provider.

Q: Can Nystaderm-S be used for ringworm (tinea corporis)?

A: Nystaderm-S is officially indicated for the management of Candida overgrowth (candidiasis). Ringworm, which is a condition caused by a different type of fungus (tinea corporis), is not a listed indication for this oral suspension.

Q: Are there any age restrictions for using Nystaderm-S?

A: The use of Nystaderm-S oral suspension is established and permitted across a wide range of ages. This includes adults, children, and neonates (newborns), and no specific age restrictions are listed in the contraindications.

Q: What is the eligibility criteria for who can use Nystaderm-S?

A: Eligibility is defined by the medicine's official indication (candidiasis) and patient history. The medication is absolutely prohibited for use in patients with a history of hypersensitivity to nystatin. It is also restricted only to localized treatment and must not be used for widespread internal fungal infections.

Q: Is Nystaderm-S known to cause any long-term skin changes?

A: Because this medicine is an oral suspension that is negligibly absorbed into the bloodstream and is not a topical steroid, warnings about typical long-term skin changes associated with topical treatments are not generally included in official documents.

Q: Are there common reasons why a doctor might decide to stop a prescription of Nystaderm-S?

A: Regulatory documents explicitly advise that if signs of irritation or sensitization occur, the use of the medication should be discontinued. This type of adverse reaction is a common, official reason for a healthcare provider to stop the treatment.

Q: Does Nystaderm-S contain any inactive ingredients that commonly cause reactions?

A: The complete list of both active and inactive ingredients (excipients) used in the formulation is formally documented in the regulatory labeling. The documentation of inactive ingredients allows patients and providers to identify substances that may cause known reactions.

Q: Is Nystaderm-S generally used for short-term or long-term issues?

A: The medicine is generally intended for short-term use. This is because the treatment duration is defined by the quick resolution of symptoms from the localized infection, plus a mandatory period of 48 hours to help prevent relapse.

Q: Can I use Nystaderm-S for conditions other than those listed on the label?

A: Regulatory agencies define the specific approved conditions for which the medicine has been tested and authorized. Using the medicine for conditions other than those listed on the official label is considered off-label use, which falls outside the scope of official recommendations.

Q: Does Nystaderm-S have a known potential for abuse or dependence?

A: Official regulatory documents, which include a section on Drug Abuse and Dependence, do not list nystatin as a medicine with a known potential for abuse or physical dependence.

Q: Are there any known issues with using Nystaderm-S if I have diabetes?

A: The official labeling lists the complete composition, including all inactive ingredients. If the formulation contains ingredients like sucrose (sugar), the presence of such ingredients is a factor that is noted in official documents for use consideration.

Q: Does Nystaderm-S help with the redness and inflammation associated with the treated condition?

A: As a monopreparation of nystatin, the medicine is described only as an antifungal agent, and its primary function is to destroy fungal cells. It is not described in official documents as containing an anti-inflammatory component like a corticosteroid to directly address redness and inflammation.

How should Nystaderm-S be stored and disposed of?

Storage Requirements

Official regulatory information requires Nystaderm-S Oral Suspension to be stored at refrigerator temperatures, specifically between 2 C to 8 C (36 F to 46 F). The medicine must not be frozen and should be stored in its original container to protect it from light.

Stability and Child Safety

Once the bottle has been opened, the suspension has a limited stability period and must be discarded after 4 weeks. As with all medicines, the product must be kept out of the sight and reach of children.

Disposal Instructions

For disposal of unused or expired Nystaderm-S, regulatory labeling specifies that the medicine must not be disposed of via wastewater or placed in general household waste. Consultation with a pharmacist or local waste management service is required for proper disposal.

Nystaderm-S